Peisi Li
Sun Yat-sen University
8 Papers
Peisi Li is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
m 6 A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways
Ru Deng,Yi-Kan Cheng,Shu-Biao Ye,Jianwei Zhang,Runqing Huang,Peisi Li,Huashan Liu,Qiling Deng,Xianrui Wu,Ping Lan,Yanhong Deng +10 more
TL;DR: It is concluded thatMETTL3 played a tumor-suppressive role in CRC cell proliferation, migration and invasion through p38/ERK pathways, which indicated that METTL3 might be a novel marker for CRC carcinogenesis, progression and survival.
Tumor-secreted IFI35 promotes proliferation and cytotoxic activity of CD8+ T cells through PI3K/AKT/mTOR signaling pathway in colorectal cancer
Peisi Li,Daohong Zhou,Dong-Wen Chen,Yi Kan Cheng,Yuan Chen,Zhen Lin,Zhihong Huang,Jiawei Cai,Wen-Feng Huang,Yan-Yun Lin,Hao Ke,Jia Long,Yifeng Zou,Shu Biao Ye,P. Lan +14 more
TL;DR: In this paper , the expression of IFI35 was found to be correlated with increased proliferation and cytotoxicity of CD8 + T cells in colorectal cancer cells and increased the efficacy of CAR-T cells in immunotherapeutic treatment.
High-throughput proteomics profiling-derived signature associated with chemotherapy response and survival for stage II/III colorectal cancer
Shu Biao Ye,Yi Kan Cheng,Peisi Li,Lin Zhang,Lianhai Zhang,Yan Huang,Ping Chen,Yian Wang,Chao Wang,Jianhong Peng,Lisa Ling,Xiaojian Wu,Jun Qin,Zihuan Yang,P. Lan +14 more
TL;DR: Wang et al. as mentioned in this paper used high-throughput proteomics to analyze tumor and adjacent normal tissues of stage II/III colorectal cancer patients with /without relapse to identify potential markers for predicting prognosis and benefit from ACT.
The Predictive Value of Estrogen Receptor 1 on Adjuvant Chemotherapy in Locally Advanced Colorectal Cancer: A Retrospective Analysis With Independent Validation and Its Potential Mechanism.
TL;DR: The present study manifest clinical validity of ESR1 expression as a predictive biomarker on 5-FU-based adjuvant chemotherapy in stage II–III CRC as well as an external independent cohort (n = 511) from GSE39582 for further validation.